Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Stemberg cells

Blood

Volumn 99, Issue 1, 2002, Pages 258-267

  Oelmann, Elisabeth ^a,b   Herbst, Hermann ^c   Zühlsdorf, Michael ^c   Albrecht, Oliver ^c   Nolte, Annette ^c   Schmitmann, Christiane ^c   Manzke, Oliver ^c   Diehl, Volker ^c   Stein, Harald ^c   Berdel, Wolfgang E ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 5; INTERLEUKIN 7; INTERLEUKIN 8; LYMPHOTOXIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; AUTOCRINE EFFECT; CELL SURVIVAL; CLINICAL ARTICLE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIXED LYMPHOCYTE CULTURE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; T CELL LYMPHOMA;

EID: 0036095975     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.1.258     Document Type: Article

References (87)

1. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
2. Cytokines in malignant lymphomas
3. Hodgkin's disease
4. Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease
5. Expression of interleukin-1 in Reed-Sternberg cells and neoplastic cells from the true histiocytic malignancies
6. Characterization of a novel Hodgkin cell line. HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice
7. Lymphotoxin, tumor necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases
8. Frequent expression of IL-7 gene transcripts in tumor cells of classical Hodgkin's disease
9. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils
10. Immune escape mechanisms in Hodgkin's disease
11. The matrix metalloproteinases and their natural inhibitors: Prospects for treating degenerative tissue diseases
12. The matrix degrading metalloproteinases
13. Tumor cell interactions with the extracellular matrix during invasion and metastasis
14. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
15. Proteases and protease inhibitors in tumor progression
16. Control of matrix metalloproteinase activity in cancer
17. Regulation of matrix metalloproteinase expression in tumor invasion
18. Membrane-type metalloproteinases in tumor invasion
19. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity
20. cDNA cloning and expression of a metalloproteinase inhibitor related to tissue inhibitor of metalloproteinases
21. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIM P-3) and mapping of the TIMP3 gene to chromosome 22
22. Cloning of cDNAs encoding human TIMP-3, a novel member of the tissue inhibitor of metalloproteinase family
23. Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family
24. Cloning and characterization of human tissue inhibitor of metalloproteinase-3
25. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
26. Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 A resolution
27. Structural properties of matrix metalloproteinases
28. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1
29. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2 and -3 in rabbit aortic smooth muscle cells
30. TIMP-1 protein expression is stimulated by IL-1β and IL-6 in primary rat hepatocytes
31. Stimulation of TIMP-1 production by oncostatin M in human articular cartilage
32. Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA)
33. Translational augmentation of pro-matrix metalloproteinase 3 (prostromelysin 1) and tissue inhibitor of metalloproteinases (TIMP)-1 mRNAs induced by epidermal growth factor in human uterine cervical fibroblasts
34. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes
35. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells
36. Regulation of tissue inhibitor of metalloproteinases-1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures
37. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes
38. Tissue inhibitor of metalloproteinases-3 inhibits shedding of L-selectin from leukocytes
39. Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas
40. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas
41. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells
42. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells
43. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases
44. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2)
45. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1
46. Tissue inhibitor of metalloproteinase-2 stimulates fibro-blast proliferation via a cAMP-dependent mechanism
47. K562 cells produce and respond to human erythroid-potentiating activity
48. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro
49. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1
50. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells
51. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines
52. Tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues
53. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver
54. Temporal and spatial patterns of transin/stromelysin RNA expression following toxic injury in rat liver
55. Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease
56. In situ hybridization for procollagen types I, III and IV mRNA in normal and fibrotic rat liver. Evidence for predominant expression in nonparenchymal liver cells
57. Specificity of riboprobes for intracellular RNA in hybridization histochemistry
58. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
59. Cytolytic T-cell cytotoxicity is mediated through perforin and fas lytic pathways
60. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
61. Bcl-2 expression inhibits prostaglandin E2-mediated apoptosis in B cell lymphomas
62. Altered tumor growth and metastasis of a T-cell lymphoma in TIMP-1 transgenic mice
63. Constitutive nuclear factor-KB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells
64. The molecular and cellular origins of Hodgkin's disease
65. Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells
66. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo
67. + T cells showing abnormal recognition of DR antigens in lymphoid organs involved by Hodgkin's disease
68. Tissue inhibitor of metalloproteinase-2 induces apoptosis in human T lymphocytes
69. Downregulation of FAS ligand by shedding
70. Fas-based lymphocyte-mediated cytotoxicity against syngeneic activated lymphocytes: A regulatory pathway?
71. Selective regulation of apoptosis: The cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway
72. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-α receptors in a human colon adenocarcinoma (Colo 205) cell line
73. Viral inhibition of inflammation: Cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme
74. A major retroviral core protein related to EPA and TIMP
75. Tax proteins of human T-cell leukemia virus type 1 and 2 induce expression of the gene encoding erythroid potentiating activity (tissue inhibitor of metalloproteinase-1, TIMP-1)
76. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease
77. + Hodgkin's disease
78. High expression of the CC chemokine TARC in Reed-Sternberg cells: A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma
79. Regulation of B-cell lymphoma growth in syngeneic SJL/J mice. Establishment of tumor dormancy following administration of anti-CD4 monoclonal antibody into tumor-bearing mice
80. + CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL
81. Depletion of IL-10- and TGF-1β-producing regulatory γδ T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells
82. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer
83. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival
84. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study
85. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP)
86. Crystal structure of the complex formed by the membrane type 1 matrix metalloproteinase with the tissue inhibitor of metalloproteinase-2, the soluble progelatinase A receptor
87. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity